Send to

Choose Destination
Transl Lung Cancer Res. 2017 Apr;6(2):113-118. doi: 10.21037/tlcr.2017.04.02.

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer.

Author information

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Department of Radiation Oncology, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.


For patients with inoperable stage II-III non-small cell lung cancer (NSCLC), the backbone of curative intent therapy is concurrent chemoradiotherapy (CRT). As checkpoint inhibitors have shown clinical benefit in the setting of metastatic NSCLC, additional study is necessary to understand their role in patients receiving CRT. When integrating immunotherapy with radiotherapy (RT) for cure, clinicians will need to consider synergy, timing, doses, and safety among the combination of therapies. This article seeks to review data evaluating interactions, temporal sequencing, fractionation, and overlapping toxicity profiles of thoracic chemoradiation and immunotherapy.


Immunotherapy; PD-1; PD-L1; chemoradiation; non-small cell lung cancer (NSCLC)

Conflict of interest statement

Conflicts of Interest: Dr. Jabbour has research funding from Merck Sharp & Dohme. The other authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center